AKT News

News

Capivasertib Plus Palbociclib and Fulvestrant Demonstrated Safety, Tolerability Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

01/16/2024

Stephanie Holland

Updated phase 1b results from the CAPItello-292 study demonstrated that capivasertib plus palbociclib and fulvestrant was safe and tolerable among heavily pre-treated patients with HR-positive, HER2-negative advanced breast cancer.

Updated phase 1b results from...

01/16/2024

Oncology

News

Addition of Capivasertib to Fulvestrant Improved PFS Across All Key AKT Pathway Alterations Among Patients With HR-Positive, HER2-Negative Breast Cancer

12/19/2023

Allison Casey

According to an exploratory analysis of the CAPItello-291 trial, the benefit to progression-free survival seen with the addition of capivasertib to fulvestrant was consistent among patients with alterations in all 3 key genes within the AKT...

According to an exploratory...

12/19/2023

Oncology

News

Capivasertib Plus Fulvestrant Approved for Patients With HR-Positive, HER2-Negative Breast Cancer

11/20/2023

Stephanie Holland

Based on results from the phase 2 CAPItello-291 study, the FDA has approved capivasertib plus fulvestrant for patients with previously treated HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring one or more...

Based on results from the phase...

11/20/2023

Oncology

News

Capivasertib Plus Fulvestrant Prolonged PFS in HR-Positive, HER2-Negative Advanced Breast Cancer

08/02/2023

Stephanie Holland

Data from a phase 3 trial found that adding capivasertib to fulvestrant significantly prolonged progression-free survival among patients with HR-positive, HER2-negative advanced breast cancer, compared to fulvestrant alone.

Data from a phase 3 trial found...

08/02/2023

Oncology

News

Fulvestrant Plus Capivasertib Extends Survival in ER-Positive, HER2-Negative Breast Cancer

07/05/2022

Derek Cowsert

Study findings suggest fulvestrant plus capivasertib yielded consistently longer OS and PFS among patients with ER-positive, HER2-negative advanced breast cancer.

Study findings suggest...

07/05/2022

Oncology

News

No Benefit Adding Ipatasertib to First-Line Paclitaxel for PIK3CA-Altered TNBC

11/27/2021

IPATunity130 trial data showed that adding ipatasertib to paclitaxel did not improve PFS in patients with PIK3CA/AKT1/PTEN-altered TNBC.

IPATunity130 trial data showed...

11/27/2021

Oncology

News

Capivasertib Plus Paclitaxel Superior to Paclitaxel Alone for Metastatic TNBC

10/19/2020

Capivasertib in combination with paclitaxel yielded longer PFS and OS in patients with metastatic TNBC, particularly those with PIK3CA/AKT1/PTEN-altered tumors.

Capivasertib in combination with...

10/19/2020

Oncology

News

Fulvestrant–Capivasertib Combo Significantly Prolongs Survival in ER-Positive Breast Cancer

02/14/2020

Adding capivasertib to fulvestrant therapy significantly extends PFS over placebo plus fulvestrant in patients with metastatic, ER-positive breast cancer.

Adding capivasertib to...

02/14/2020

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology